-
Atezolizumab, sold
under the
brand name
Tecentriq among others, is a
monoclonal antibody medication used to
treat urothelial carcinoma, non-small cell...
- (FDA). In the
European Union,
atezolizumab is the
first PD-(L)1
cancer immunotherapy for
subcutaneous injection.
Atezolizumab/hyaluronidase, sold
under the...
-
Atezolizumab/hyaluronidase, sold
under the
brand name
Tecentriq Hybreza, is a fixed-dose
combination medication used for the
treatment of non-small cell...
-
combination of
tiragolumab and
atezolizumab reduced the risk of
disease progression or
death by 38%
compared to
atezolizumab monotherapy. In a
subset of...
-
Atezolizumab (Tecentriq) is a
fully humanised IgG1 (immunoglobulin 1)
antibody developed by
Roche Genentech. In 2016, the FDA
approved atezolizumab for...
- yet FDA- or
other regulator-approved treatment,
except PDL1
inhibitor atezolizumab for the ultra-rate
diagnosis of
alveolar soft part sarcoma.
Other strategies...
- is a
phase 3,
randomized study of
zanzalintinib in
combination with
atezolizumab versus regorafenib in
metastatic colorectal cancer. STELLAR-304 (NCT05678673)...
- Epizyme's EZH2
inhibitor tazemetostat would be
synergistic with Genentech's
atezolizumab. In
August 2016, the
company began a
collaboration with
Carmot Therapeutics...
-
small cell lung cancer:
Nivolumab (Opdivo), a PD-1
inhibitor (2018)
Atezolizumab (Tecentriq), a PD-L1
inhibitor (2018) Tarlatamab, a bi-specific T-cell...
-
treat both
solid tumors and lymphomas. In May 2016, PD-L1
inhibitor atezolizumab was
approved for
treating bladder cancer. LAG-3
Inhibitors In 2022, the...
